Erin

Erin Harris

Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.

ARTICLES BY ERIN HARRIS

  • Aro Biotherapeutics Talks Series A Financing, Future of Centyrins

    Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. Earlier this month, Aro announced the closing of an $88 million Series A financing. The proceeds from the Series A will be used to advance the company’s lead therapeutic candidates into clinical development, with an initial focus in rare genetic and immune disorders. I caught up with Aro Biotherapeutics Susan Dillon, Ph.D., co-founder and CEO to learn more about mass production of Centyrins, their line of RNA-based therapies, and more.

  • A Recap Of ARM’s Cell And Gene Therapy State Of The Industry And Panel Discussion

    During JP Morgan 2021, ARM’s CEO Janet Lambert and her team crafted an extremely informative Cell and Gene Therapy State of the Industry address. During her address, Lambert provided a look back at 2020’s highlights and challenges. She stated that COVID-19 provided disruptions to clinical trials. Regulatory was slammed with COVID-19-related demands and had less bandwidth for cell and gene therapies, and the political climate posed problems to sector. The sector had a recording-setting year in terms of financing with $20 billion in investment in this space — more than double in 2019. Public financing was especially strong in 2020, and IPOs were double the previous record set in 2018.

  • The Business Of Biotech Cell & Gene Miniseries Kicks Off With Selecta

    My colleague, Chief Editor of Bioprocess Online’s Matt Pillar, hosts The Business of Biotech podcast, and I’m guest hosting a five-part miniseries focused on cell and gene therapy. Throughout the miniseries, you’ll hear from executives from Acepodia, Orchard Therapeutics, Celyad Oncology, and Sio Gene Therapies. You’ll hear about manufacturing wins and fumbles, unmet medical need, the participant’s path to the C-suite, and more.

  • Developing A Therapeutic Platform To Enable Immunotherapy For Liver Tumors

    The deep and durable responses achieved in certain indications with immunotherapies have largely eluded those patients suffering with liver tumors.

  • How Biotechs Shape CDMO Capabilities

    CEO Tom Hochuli and President and Managing Director Dr. Stefan Beyer answer my questions about how biotechs have helped shape the new facility’s capabilities.

  • Inside Omega Therapeutics’ Epigenomic Controllers™

    Omega Therapeutics is developing novel engineered and modular therapeutics, called Omega Epigenomic Controllers™, that are designed to target with high specificity and downregulate or upregulate the level of expression of any of the 25,000+ human genes, individually or collectively, with controlled durability, to treat and potentially cure disease.

  • What The Gene Therapy Sector Doesn’t Understand About CRISPR

    I sat down with Sadik Kassim, Chief Technical Officer at Vor Biopharma to discuss the benefits of CRISPR-engineered stem cell therapies, the challenges and feasible solutions, what’s next, and more.

  • The Ethical Implications Of Editing A Genome

    CRISPR is in fact safe if used in the appropriate context. Indeed, we have already seen quite a few trials emerge where they propose to use CRISPR for Tay-Sachs disease, congenital blindness, as well as more creative approaches to use CRISPR gene editing for cancer immunotherapy.

  • The History Of CRISPR-CAS9 Gene Editing Tool

    The concept of gene editing has been around for decades. CRISPR-CAS9 is a gene editing tool. If we look at gene editing tools, they have been around for quite some time. CRISPR is the most recent iteration of gene editing tools, and it has enabled in a very flexible and cost-efficient manner to edit the genome.

  • Inside Bone Therapeutics, Catalent Pharma Solutions Manufacturing Partnership

    Catalent Pharma Solutions recently completed the acquisition of Bone Therapeutics’ manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS). Following completion of the transaction, SCTS’ manufacturing infrastructure and production operating teams have now become part of Catalent’s Cell & Gene Therapy division. I caught up with Miguel Forte, CEO of Bone Therapeutics to learn more about what this acquisition means for the clinical and commercial manufacturing of the company’s ALLOB therapy.